In this video lecture, Dr. Thomas Coates discusses:
- How non-transferrin-bound and reactive iron drive tissue toxicity in transfused hemoglobinopathies.
- How erythropoietic activity, transferrin saturation, and duration of iron exposure influence organ damage.
- Why continuous chelator exposure, adherence, and MRI monitoring are central to managing iron toxicity.
Dr. Coates is Section Head of Hematology at Children’s Hospital Los Angeles and Professor of Pediatrics and Pathology at the University of Southern California Keck School of Medicine. He completed his undergraduate training in physics and received his medical degree from the University of Michigan.
His clinical and research interests span Classical Hematology, including sickle cell disease, thalassemia, neutrophil disorders, and iron overload in both children and adults. His research applies engineering‑based approaches to the study of sickle cell disease, with direct measurement of microvascular blood flow and autonomic nervous system function during vaso‑occlusive events. He has been continuously funded by the NIH as a principal investigator for over 30 years and served as lead principal investigator on an NHLBI Excellence in Hemoglobinopathies Research Award focused on human pain responses in sickle cell disease and other chronic anemias. Clinically, he consults and manages pediatric and adult patients with rare disorders in Classical Hematology, including iron overload syndromes, hemoglobinopathies, and functional neutrophil disorders.
(Video Lecture Summary)
Introduction
Dr. Thomas Coates reviews the management of iron toxicity and iron overload in transfused patients with hemoglobinopathies. Rather than focusing primarily on ferritin levels or total body iron content, he frames the goal of treatment as protecting tissues from exposure to reactive, ferrous iron.
Iron toxicity reflects both the amount of reactive iron to which tissues are exposed and the duration of that exposure. Iron input from absorption and transfusion contributes to this process, but erythropoietic activity is a major determinant of whether reactive iron is present. Duration is also important because even relatively small amounts of reactive iron can cause substantial damage when exposure continues over many years.
Reactive Iron and Tissue Damage
Iron bound to transferrin is not readily converted into the toxic form in plasma. In contrast, non-transferrin-bound iron (NTBI) can be converted into reactive ferrous iron. Ferrous iron interacts with oxidants such as hydrogen peroxide to generate highly reactive oxidants, amplifying oxidative tissue damage. An important distinction is that iron chelation can rapidly remove NTBI and reduce toxic iron exposure, even though removal of stored iron from tissues occurs much more slowly.
Toxic Iron Versus Stored Iron
Dr. Coates illustrates this distinction with patients with thalassemia and severe cardiac iron overload treated with continuous intravenous deferoxamine. Cardiac function improved within approximately three months, despite substantial cardiac iron remaining detectable by MRI.
Liver iron declined considerably faster than cardiac iron. He describes a half-life of approximately four to six months for removal of liver iron compared with approximately 12 to 16 months for cardiac iron. The rapid improvement in cardiac function therefore could not be explained simply by removal of stored cardiac iron.
Instead, circulating toxic iron falls rapidly when chelator is present. NTBI can fall to nearly zero shortly after deferoxamine appears in the plasma and remains suppressed while the chelator is circulating. When chelation stops, NTBI rises again. MRI detects stored ferric iron rather than the reactive ferrous iron responsible for toxicity.
Why Continuous Chelator Exposure Matters
Clinical outcomes also reflect the importance of continuous chelator exposure. Dr. Coates presents survival data showing substantially better outcomes among patients with thalassemia who took their chelator nearly every day compared with patients who took it only intermittently. His central point is that adherence to daily chelation may be as important as, or more important than, chelator dose. Maintaining chelator exposure limits the amount of time during which tissues are exposed to toxic iron.
Iron Regulation and Hepcidin
The reticuloendothelial system, particularly in the liver and spleen, has a central role in iron regulation. The liver responds to iron stores by producing hepcidin, which regulates ferroportin, the transporter through which ferrous iron exits cells.
Iron is continually recycled from aging red blood cells. Macrophages process these cells and release iron, which can either be stored or returned to the circulation. Intracellular ferrous iron promotes ferritin production, and ferritin converts and stores iron in the ferric form, reducing its toxicity.
Ferritin levels therefore respond to iron, but they also rise with inflammation. This contributes to the limitations of ferritin as a measurement of total body iron.
Erythropoiesis and the Formation of NTBI
Under normal conditions, iron released from storage binds transferrin and is transported to the bone marrow for erythropoiesis. Utilization of this iron regenerates unsaturated transferrin, allowing additional circulating iron to be bound.
When erythropoiesis is ineffective or absent, unsaturated transferrin is not adequately regenerated and transferrin becomes saturated. Iron then binds to citrate, forming NTBI. Unlike transferrin-bound iron, this iron can be reduced to the reactive ferrous form and contribute to tissue toxicity.
How Reactive Iron Enters Organs
Ferrous iron can enter tissues through divalent metal transport pathways that are not regulated according to the body’s iron burden. Dr. Coates highlights the pituitary, pancreas, and heart as important sites of this process.
Once inside these tissues, reactive iron contributes to toxicity and is subsequently incorporated into ferritin as stored ferric iron. This stored iron can then be detected by MRI. The process helps explain why circulating NTBI can cause progressive endocrine and cardiac iron loading.
Why Iron Toxicity Differs Across Disorders
Dr. Coates compares iron loading across sickle cell disease, thalassemia, and bone marrow failure. Patients with sickle cell disease receiving chronic transfusions can develop very high liver iron concentrations while having relatively little pancreatic or cardiac iron because their active erythropoiesis continues to utilize iron and regenerate unsaturated transferrin.
In thalassemia and bone marrow failure, ineffective or absent erythropoiesis limits this protective mechanism. NTBI levels can therefore remain high, contributing to pancreatic and cardiac iron accumulation.
Measuring Total Body Iron
Liver iron concentration is presented as the best measurement of total body iron stores, with a very strong relationship between liver iron and total body iron content.
Ferritin also correlates with iron burden, but individual measurements can vary substantially. Iron status and inflammation both influence ferritin, and ferritin may rise even when liver iron remains low and stable. Dr. Coates therefore cautions against increasing chelation based on ferritin alone because doing so can lead to over-chelation and toxicity.
Ferritin trends should be periodically validated using MRI measurements of iron burden.
Erythropoiesis and Organ Iron Loading: A Clinical Example
Dr. Coates illustrates the relationship between erythropoietic activity and NTBI using a patient with sickle cell disease who developed massive liver iron accumulation while remaining nonadherent to chelation. Despite this iron burden, she initially had no pancreatic or cardiac iron.
When intensified transfusion suppressed her erythropoietic activity, pancreatic and cardiac iron began to accumulate despite persistently high liver iron throughout the period. He uses this case to demonstrate how reduced erythropoiesis can alter iron handling and increase NTBI-mediated organ loading.
Adherence and Extrahepatic Iron Clearance
A patient with transfusion-dependent thalassemia provides another illustration of the importance of continuous chelation. Despite taking deferasirox five days per week, she developed substantial pancreatic and cardiac iron loading.
Rather than increasing the dose, Dr. Coates instructed her to take the same chelator seven days per week. Her liver, pancreatic, and cardiac iron subsequently improved. Even after the dose was later reduced as liver iron approached normal levels, pancreatic and cardiac iron continued to clear.
This case reinforces his emphasis on continuous exposure to chelator rather than simply increasing the dose.
Iron Toxicity and Endocrine Function
A third patient with thalassemia developed severe liver, pancreatic, pituitary, and cardiac iron loading after years of poor chelation adherence. After becoming adherent to continuous combination chelation, his liver iron declined rapidly while extrahepatic iron cleared more gradually.
Importantly, pituitary function and growth improved before pituitary iron measured by MRI had normalized. Cardiac function also remained preserved despite measurable cardiac iron. Dr. Coates again uses this distinction to demonstrate that chelation can protect organ function by reducing toxic iron exposure even while stored iron remains detectable.
Managing Iron Overload Over Time
Iron toxicity generally develops over years. Dr. Coates cautions against reacting to increases in ferritin by attempting to reduce iron burden too aggressively over a period of months. Excessive dosing may make chelation difficult to tolerate and undermine adherence.
Instead, clinicians generally have time to work with patients to establish a sustainable chelation regimen. Iron cardiomyopathy with left ventricular dysfunction or arrhythmia is an important exception and represents a medical emergency requiring rapid intervention.
Available Iron Chelators
Dr. Coates discusses three iron chelators: deferoxamine, deferasirox, and deferiprone. Deferoxamine has a very short half-life and must be administered over many hours to be effective. Deferasirox has a longer half-life and enters cells, allowing it to provide intracellular protection. Deferiprone has a short half-life but provides strong intracellular protection against ferrous iron damage.
For patients with very high liver iron, he describes using combination chelation because a single chelator may not be sufficient to control circulating NTBI. When chelator toxicity develops, he favors reducing the dose rather than having patients repeatedly skip doses, which can leave them without chelator exposure for prolonged periods.
Deferasirox Dosing and Continuous Coverage
Although deferasirox is labeled for once-daily administration, Dr. Coates describes substantial variability in its half-life between patients. In some individuals, circulating drug may disappear within approximately 12 hours, leaving part of the day without chelator coverage.
His practice therefore divides deferasirox dosing approximately every 12 hours to maintain more continuous exposure. He presents data in which splitting the same total daily dose was associated with declining ferritin and increased total deferasirox exposure.
The rationale again reflects the central goal of treatment: maintaining circulating chelator to minimize periods of NTBI exposure.
Conclusion
Dr. Coates concludes that iron toxicity is driven by exposure to NTBI over time. Toxicity is lower when erythropoiesis remains active and substantially greater when erythropoiesis is ineffective or absent, as occurs in thalassemia and several bone marrow failure disorders.
NTBI can be neutralized rapidly when chelator is circulating, while stored tissue iron takes much longer to remove. Missing even a few doses each week can permit continued cardiac and endocrine iron loading. For this reason, adherence and continuous chelator exposure are central to controlling iron toxicity, while MRI monitoring helps clinicians assess the underlying tissue iron burden and guide treatment.